Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.

Annual Revenue ($)

Edwards Lifesciences revenue was $4.39 b in FY, 2020 which is a (0.9%) year over year increase from the previous period.

Quarterly Revenue ($)

FY, 2018FY, 2019FY, 2020
Revenue$3.72 b$4.35 b$4.39 b
Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021
Revenue$993 m$1.09 b$1.09 b$1.13 b$925 m$1.14 b$1.22 b$1.38 b

Annual Growth Rate (%)

Revenue Breakdown

Business Segment

Geographic Segment

Edwards Lifesciences revenue breakdown by business segment: 65.1% from Transcatheter Aortic Valve Replacement, 17.4% from Surgical Structural Heart, 16.5% from Critical Care and 1.0% from Other

Edwards Lifesciences revenue breakdown by geographic segment: 57.4% from United States, 22.2% from Europe, 10.5% from Japan and 9.9% from Rest of World

FY, 2019FY, 2018FY, 2020
Transcatheter Mitral and Tricuspid Therapies$28.2 m$41.8 m
Transcatheter Aortic Valve Replacement$2.74 b$2.86 b
Surgical Structural Heart$841.7 m$761.8 m
Critical Care$740.2 m$674.5 m$725.4 m
Transcatheter Heart Valve Therapy$2.29 b
Surgical Heart Valve Therapy$761.6 m
FY, 2019FY, 2018FY, 2020
United States$2.53 b$2.06 b$2.52 b
Europe$941.2 m$885.1 m$973.6 m
Japan$444.7 m$396.8 m$460.1 m
Rest of World$429.4 m$385.6 m$435.8 m

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Footer menu